Evidence map›Paper›PMID 41840629›Full record

ArticleMolecular cancer2026

GPR183 potentiates CAR-T cell infiltration and antitumor immunity through a positive feedback loop involving the oxysterol 7α,25-OHC.

Rui Guo, Chang Guo, Sen Qin, Zhiwen Lin, Jinlian Tong, Yiran Wang, Zixuan Zhao, Wen Zuo, Qing Gao, Qin Tan and 1 more

Abstract read
In one paragraph

Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rui GuoCenter of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Chang GuoCenter of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Sen QinCenter of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Zhiwen LinCenter of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Jinlian TongCenter of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Yiran WangCenter of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Zixuan ZhaoCenter of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Wen ZuoCenter of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Qing GaoCenter of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Qin TanCenter of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China. tanqin4847@bjhmoh.cn.
Jie MaCenter of Biotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China. majie4685@bjhmoh.cn.

Funding

National High Level Hospital Clinical Research Funding BJ-2025-122National High Level Hospital Clinical Research Funding BJ-2025-151National Natural Science Foundation of China 52273281National Natural Science Foundation of China 82373272
6 · The paper itself

Abstract

backgroundInsufficient T cell infiltration into solid tumors represents a major barrier to effective immunotherapy, particularly in the context of CAR-T therapy. Identifying key molecules capable of promoting T cell migration to tumor sites is therefore critical. GPR183 (EBI2), a receptor for oxidized sterols, has not yet been fully characterized in terms of its role in antitumor T cell immunity or its potential for application in CAR-T cell engineering.

methodsPublic single-cell transcriptomic data from breast cancer and ovarian cancer were analyzed to identify distinct expression patterns of GPR183 across T cell subsets, which were validated using flow cytometry. Functional assays, including in vitro Transwell migration experiments, as well as GPR183 knockout and overexpression models, demonstrated that GPR183 regulates T cell migration. To investigate the underlying molecular mechanisms, we employed ligand stimulation, co-culture systems, and transcriptome sequencing. Furthermore, we generated HER2-targeted CAR-T cell models with either GPR183 knockdown or overexpression, and systematically evaluated the impact of GPR183 on CAR-T cell function through in vitro cytotoxicity assays, IFN-γ secretion measurements, and in vivo tumor xenograft models in mice.

resultsSingle-cell analysis revealed that GPR183high T cells exhibit a central memory phenotype and are enriched in migration-related signaling pathways. Functional experiments confirmed that GPR183 acts as a key positive regulator of T cell migration. Mechanistically, direct contact between T cells and tumor cells induced upregulation of CH25H and CYP7B1 in tumor cells, leading to increased production of 7α,25-OHC, which activated GPR183 and further enhanced its expression, establishing a positive feedback loop. In the HER2-CAR-T model, GPR183 overexpression significantly enhanced tumor infiltration, IFN-γ secretion, and tumor cell killing, and resulted in an additively improved antitumor efficacy in vivo.

conclusionThis study reveals, for the first time, that the GPR183-mediated positive feedback loop is a critical novel mechanism governing T cell tumor infiltration. Enhancing GPR183 expression through genetic engineering represents a promising strategy that significantly improves the migratory capacity and antitumor functionality of CAR-T cells, thereby providing a new therapeutic target and theoretical foundation for overcoming current limitations in the treatment of solid tumors.

Indexed as

Immunotherapy, AdoptiveOxysterolsReceptors, Chimeric AntigenReceptors, G-Protein-CoupledT-LymphocytesAnimalsBreast NeoplasmsCell Line, TumorCell MovementFeedback, PhysiologicalFemaleHumansMiceXenograft Model Antitumor AssaysGPR183 protein, humanOxysterolsReceptors, Chimeric AntigenReceptors, G-Protein-CoupledCAR-T therapyGPR183Positive feedback loopSolid tumor treatmentT cell migration

Identifiers

PMID41840629
PMCPMC13107666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.